Pasteur Institute
Ho Chi Minh City, Vietnam
NCT Number: NCT03098628
This is a single-blind, open-label, randomised controlled trial with five groups. There are four different Pneumococcal Conjugate Vaccine (PCV) schedules to be evaluated.
Looking for future studies?
Notify Me8 week–10 week
All sexes
Interventional
Phase 2 / Phase 3
Ho Chi Minh City, Vietnam
This is a single-blind, open-label, randomised controlled trial with five groups. There are four different PCV schedules to be evaluated: a 0+1 schedule of PCV10 at 12 months of age (Group V), a 0+1 schedule of PCV13 at 12 months of age (Group W), a 1+1 schedule of PCV10 at 2 and 12 months of age (Group X), and a 1+1 schedule of PCV13 at 2 and 12 months of age (Group Y); along with a control group that receives a dose of PCV10 at 24 months of age (Group Z). Additionally, all participants will receive four doses of Infanrix-hexa at 2, 3, 4 and 18 months of age.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Additionally, enrolment will be deferred and infants asked to return to the health centre one week later for reassessment if they have at least one of the following deferral criteria:
PCV vaccination
Time frame: 12 months post vaccination, i.e. 24 months of age
Evaluate the effect of a 0+1 PCV schedule administered at 12 months of age on Nasopharngeal Carrige (NP) carriage during the first two years of life, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls
Time frame: 12 months post last vaccination, i.e. 24 months of age
Evaluate the effect of a 1+1 PCV schedule administered at 2 and 12 months of age on NP carriage during the first two years of life, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls.
Time frame: 12 months post vaccination, i.e. 24 months of age
i) To evaluate the immune responses to a 0+1 PCV schedule at 12 months of age, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls;
Time frame: 12 months post last vaccination, i.e. 24 months of age
ii) To evaluate the immune responses to a 1+1 PCV schedule at 2 and 12 months of age, comparing a) PCV10-vaccinated and b) PCV13-vaccinated participants with unvaccinated controls;
Murdoch Childrens Research Institute
Other
Trial of Simplified Pneumococcal Vaccination in Vietnam II: The Herd Immunity Approach
Acronym: VPTII
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05788510
Pneumococcal Vaccine
Pontoise, France
View Trial DetailsNCT05721092
Pneumococcal Vaccine
Chennai, Tamil Nadu, India
View Trial DetailsNCT01521897
Pneumococcal Vaccine, Streptococcus Pneumoniae
Kasuga, Fukuoka, Japan
View Trial DetailsNCT00689351
Disease, Pathologic Processes
Incheon, Bupyeong-gu, South Korea
View Trial Details